Cytori Therapeutics, Inc. (NASDAQ: CYTX) is committed to becoming the global leader in regenerative medicine. The company focuses on providing patients with new options for reconstructive and aesthetic surgery, developing treatments for cardiovascular disease, and banking adipose-derived, adult stem and regenerative cells (ADRCs). To meet its objective, Cytori developed Celution® Technology to separate and concentrate a patient’s own ADRCs for delivery back to the same patient in a single surgical procedure. For further information, visit the Company’s web site at www.cytoritx.com.
- 17 years ago
QualityStocks
Cytori Therapeutics, Inc. (NASDAQ: CYTX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Launches 12-Month AI-Driven Marketing Campaign With AGORACOM
LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) announced a 12-month online marketing campaign with…
-
QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Strengthens Balance Sheet with Full Conversion of $13.3 Million Notes
Datavault AI (NASDAQ: DVLT), a pioneer in AI-driven data monetization, announced the full conversion of…
-
Nightfood Holdings Inc. (NGTF) Offering a Portfolio of AI-Powered Robots Designed to Streamline Operations and Enhance Efficiency
Nightfood Holdings has a lineup of AI-powered robots to streamline operations across industries, weaving technology…